• Je něco špatně v tomto záznamu ?

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

W. Reinisch, WJ. Sandborn, S. Danese, X. Hébuterne, M. Kłopocka, D. Tarabar, T. Vaňásek, M. Greguš, PA. Hellstern, JS. Kim, MP. Sparrow, KJ. Gorelick, M. Hoy, M. Goetsch, C. Bliss, C. Gupta, F. Cataldi, S. Vermeire

. 2021 ; 15 (6) : 938-949. [pub] 2021Jun22

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004193

BACKGROUND AND AIMS: Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II. METHODS: TURANDOT II was a phase 2, multicentre, open-label [OL] study in patients with moderate-to-severe UC who completed TURANDOT on placebo or ontamalimab (NCT01771809). Patients were randomised to 75 mg or 225 mg ontamalimab every 4 weeks for 72 weeks [OL1]. The dosage could be increased to 225 mg from Week 8 at the investigator's discretion. All patients then received 75 mg every 4 weeks for 72 weeks [OL2], followed by 6-month safety follow-up. The primary objective was safety, measured by adverse events [AEs], serious AEs [SAEs], and AEs leading to withdrawal. Mucosal healing [MH; centrally read endoscopy] was assessed. RESULTS: Of 330 patients, 180 completed OL1; 94 escalated to 225 mg; 127 completed OL2. Overall, 36.1% experienced drug-related AEs. The most common SAE [10.0%] was worsening/ongoing UC; 5.5% of patients had serious infections, the most common being gastroenteritis [0.9%]. One death and four cancers [all unrelated to ontamalimab] occurred. No PML [progressive multifocal leukoencephalopathy]/lymphoproliferative disorders occurred. Geometric mean high-sensitivity C-reactive protein [hsCRP] and faecal calprotectin decreased across OL1 in both dose groups. The proportion of patients assigned to placebo in TURANDOT achieving MH increased from 8.8% [6/68] at baseline to 35.3% at Week 16 [24/68; non-responder imputation]. The corresponding increase in the ontamalimab group was from 23.3% [61/262] to 26.7% [70/262]. CONCLUSIONS: Ontamalimab was well tolerated up to 144 weeks in patients with moderate-to-severe UC, with good safety and efficacy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004193
003      
CZ-PrNML
005      
20220127145441.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjab023 $2 doi
035    __
$a (PubMed)33599720
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Reinisch, Walter $u Department of Internal Medicine, Medical University of Vienna, Vienna, Austria
245    10
$a Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II / $c W. Reinisch, WJ. Sandborn, S. Danese, X. Hébuterne, M. Kłopocka, D. Tarabar, T. Vaňásek, M. Greguš, PA. Hellstern, JS. Kim, MP. Sparrow, KJ. Gorelick, M. Hoy, M. Goetsch, C. Bliss, C. Gupta, F. Cataldi, S. Vermeire
520    9_
$a BACKGROUND AND AIMS: Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II. METHODS: TURANDOT II was a phase 2, multicentre, open-label [OL] study in patients with moderate-to-severe UC who completed TURANDOT on placebo or ontamalimab (NCT01771809). Patients were randomised to 75 mg or 225 mg ontamalimab every 4 weeks for 72 weeks [OL1]. The dosage could be increased to 225 mg from Week 8 at the investigator's discretion. All patients then received 75 mg every 4 weeks for 72 weeks [OL2], followed by 6-month safety follow-up. The primary objective was safety, measured by adverse events [AEs], serious AEs [SAEs], and AEs leading to withdrawal. Mucosal healing [MH; centrally read endoscopy] was assessed. RESULTS: Of 330 patients, 180 completed OL1; 94 escalated to 225 mg; 127 completed OL2. Overall, 36.1% experienced drug-related AEs. The most common SAE [10.0%] was worsening/ongoing UC; 5.5% of patients had serious infections, the most common being gastroenteritis [0.9%]. One death and four cancers [all unrelated to ontamalimab] occurred. No PML [progressive multifocal leukoencephalopathy]/lymphoproliferative disorders occurred. Geometric mean high-sensitivity C-reactive protein [hsCRP] and faecal calprotectin decreased across OL1 in both dose groups. The proportion of patients assigned to placebo in TURANDOT achieving MH increased from 8.8% [6/68] at baseline to 35.3% at Week 16 [24/68; non-responder imputation]. The corresponding increase in the ontamalimab group was from 23.3% [61/262] to 26.7% [70/262]. CONCLUSIONS: Ontamalimab was well tolerated up to 144 weeks in patients with moderate-to-severe UC, with good safety and efficacy.
650    _2
$a dospělí $7 D000328
650    12
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a C-reaktivní protein $x analýza $7 D002097
650    _2
$a molekuly buněčné adheze $x antagonisté a inhibitory $7 D015815
650    12
$a ulcerózní kolitida $x diagnóza $x farmakoterapie $x imunologie $7 D003093
650    _2
$a imunologická odpověď na dávku $7 D004306
650    12
$a monitorování léčiv $x metody $x statistika a číselné údaje $7 D016903
650    _2
$a gastrointestinální endoskopie $x metody $x statistika a číselné údaje $7 D016099
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální látky $x aplikace a dávkování $x škodlivé účinky $7 D005765
650    _2
$a lidé $7 D006801
650    _2
$a leukocytární L1-antigenní komplex $x analýza $7 D039841
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mukoproteiny $x antagonisté a inhibitory $7 D009088
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Sandborn, William J $u Department of Medicine, University of California San Diego, La Jolla, CA, USA
700    1_
$a Danese, Silvio $u Inflammatory Bowel Diseases Center, Humanitas University, Milan, Italy
700    1_
$a Hébuterne, Xavier $u University of Nice Sophia Antipolis, CHU of Nice, Nice, France
700    1_
$a Kłopocka, Maria $u Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
700    1_
$a Tarabar, Dino $u Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia
700    1_
$a Vaňásek, Tomáš $u Faculty of Medicine, Charles University Hospital, Hradec Králové, Czech Republic
700    1_
$a Greguš, Miloš $u Gastroenterology Centre, Nitra, Slovakia
700    1_
$a Hellstern, Paul A $u Gastroenterology, Nature Coast Clinical Research, Inverness, FL, USA
700    1_
$a Kim, Joo Sung $u Seoul National University College of Medicine, Seoul, South Korea
700    1_
$a Sparrow, Miles P $u Inflammatory Bowel Disease Clinic, Alfred Hospital, Melbourne, VIC, Australia
700    1_
$a Gorelick, Kenneth J $u Zymo Consulting Group, Newtown Square, PA, USA
700    1_
$a Hoy, Michael $u Shire, a Takeda company, Lexington, MA, USA
700    1_
$a Goetsch, Martina $u Shire, a Takeda company, Zug, Switzerland
700    1_
$a Bliss, Caleb $u Shire, a Takeda company, Lexington, MA, USA
700    1_
$a Gupta, Charu $u Cytel Inc., Cambridge, MA, USA
700    1_
$a Cataldi, Fabio $u Shire, a Takeda company, Lexington, MA, USA
700    1_
$a Vermeire, Séverine $u Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 15, č. 6 (2021), s. 938-949
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33599720 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145437 $b ABA008
999    __
$a ok $b bmc $g 1751600 $s 1155342
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 15 $c 6 $d 938-949 $e 2021Jun22 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace